BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results

[GlobeNewswire] – RESEARCH TRIANGLE PARK, N.C. — BioCryst Pharmaceuticals, Inc. announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting … more

View todays social media effects on BCRX

View the latest stocks trending across Twitter. Click to view dashboard

See who BioCryst is hiring next, click here to view